Silihan lan utang jangka dawa perusahaan inflarx.de (IFRX)

The initial financial momentum of InflaRx N.V. (IFRX) is supported by grants and limited sales, gradually transforming the asset into a stable profit generator. This price trajectory shown below, where the indicator is 0.00, accompanies the development of antibodies against rare autoimmune diseases, ensuring long-term revenue through patents. However, global political fragmentation and sanctions hinder the export of innovations and the supply of research materials.

A conservative investor assesses the long-term sustainability of InflaRx N.V. (IFRX) by analyzing the company's long-term debt, which records obligations with maturities exceeding one year. This indicator measures the credit load, allowing for a comparison of borrowed capital against the potential future sales of vilobelimab and grant support, which determines the biotech business's ability to scale development without risking its financial independence.